vs
Andersons, Inc.（ANDE）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Andersons, Inc.的季度营收约是REPLIGEN CORP的1.7倍（$329.5M vs $197.9M），Andersons, Inc.净利率更高（20.5% vs 6.7%，领先13.8%），REPLIGEN CORP同比增速更快（13.6% vs -2.4%），REPLIGEN CORP自由现金流更多（$17.6M vs $-77.1M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -1.8%）
安德森公司（The Andersons, Inc.）是1947年成立的美国农业企业，总部位于俄亥俄州莫米。公司起源于1940年代服务粮食行业的安德森货运站，是深耕农业领域的多元化企业，业务覆盖大宗商品贸易、可再生能源以及植物营养板块。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ANDE vs RGEN — 直观对比
营收规模更大
ANDE
是对方的1.7倍
$197.9M
营收增速更快
RGEN
高出16.0%
-2.4%
净利率更高
ANDE
高出13.8%
6.7%
自由现金流更多
RGEN
多$94.6M
$-77.1M
两年增速更快
RGEN
近两年复合增速
-1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $329.5M | $197.9M |
| 净利润 | $67.4M | $13.3M |
| 毛利率 | 70.3% | 52.5% |
| 营业利润率 | 26.6% | 9.0% |
| 净利率 | 20.5% | 6.7% |
| 营收同比 | -2.4% | 13.6% |
| 净利润同比 | 49.6% | 143.9% |
| 每股收益（稀释后） | — | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANDERGEN
| Q4 25 | $329.5M | $197.9M | ||
| Q3 25 | $295.8M | $188.8M | ||
| Q2 25 | $535.0M | $182.4M | ||
| Q1 25 | $370.8M | $169.2M | ||
| Q4 24 | $337.5M | $174.1M | ||
| Q3 24 | $231.9M | $154.9M | ||
| Q2 24 | $492.5M | $154.1M | ||
| Q1 24 | $341.4M | $151.3M |
净利润ANDERGEN
| Q4 25 | $67.4M | $13.3M | ||
| Q3 25 | $20.1M | $14.9M | ||
| Q2 25 | $7.9M | $14.9M | ||
| Q1 25 | $284.0K | $5.8M | ||
| Q4 24 | $45.1M | $-30.3M | ||
| Q3 24 | $27.4M | $-654.0K | ||
| Q2 24 | $36.0M | $3.3M | ||
| Q1 24 | $5.6M | $2.1M |
毛利率ANDERGEN
| Q4 25 | 70.3% | 52.5% | ||
| Q3 25 | 57.8% | 53.2% | ||
| Q2 25 | 29.6% | 50.0% | ||
| Q1 25 | 41.2% | 53.6% | ||
| Q4 24 | 63.1% | 26.1% | ||
| Q3 24 | 76.4% | 50.0% | ||
| Q2 24 | 35.6% | 49.8% | ||
| Q1 24 | 37.6% | 49.5% |
营业利润率ANDERGEN
| Q4 25 | 26.6% | 9.0% | ||
| Q3 25 | 8.7% | 8.9% | ||
| Q2 25 | 4.6% | 7.6% | ||
| Q1 25 | 0.9% | 3.9% | ||
| Q4 24 | 19.9% | -17.7% | ||
| Q3 24 | 26.8% | -5.1% | ||
| Q2 24 | 11.6% | 1.0% | ||
| Q1 24 | 4.1% | 1.3% |
净利率ANDERGEN
| Q4 25 | 20.5% | 6.7% | ||
| Q3 25 | 6.8% | 7.9% | ||
| Q2 25 | 1.5% | 8.2% | ||
| Q1 25 | 0.1% | 3.4% | ||
| Q4 24 | 13.4% | -17.4% | ||
| Q3 24 | 11.8% | -0.4% | ||
| Q2 24 | 7.3% | 2.2% | ||
| Q1 24 | 1.6% | 1.4% |
每股收益（稀释后）ANDERGEN
| Q4 25 | — | $0.24 | ||
| Q3 25 | $0.59 | $0.26 | ||
| Q2 25 | $0.23 | $0.26 | ||
| Q1 25 | $0.01 | $0.10 | ||
| Q4 24 | $1.31 | $-0.55 | ||
| Q3 24 | $0.80 | $-0.01 | ||
| Q2 24 | $1.05 | $0.06 | ||
| Q1 24 | $0.16 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.3M | $767.6M |
| 总债务越低越好 | $560.0M | $542.2M |
| 股东权益账面价值 | $1.2B | $2.1B |
| 总资产 | $3.7B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.45× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ANDERGEN
| Q4 25 | $98.3M | $767.6M | ||
| Q3 25 | — | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | $561.8M | $757.4M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $809.1M | ||
| Q1 24 | — | $780.6M |
总债务ANDERGEN
| Q4 25 | $560.0M | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $608.2M | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ANDERGEN
| Q4 25 | $1.2B | $2.1B | ||
| Q3 25 | $1.2B | $2.1B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q1 25 | $1.4B | $2.0B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $1.3B | $2.0B | ||
| Q1 24 | $1.3B | $2.0B |
总资产ANDERGEN
| Q4 25 | $3.7B | $2.9B | ||
| Q3 25 | $3.3B | $2.9B | ||
| Q2 25 | $3.4B | $2.9B | ||
| Q1 25 | $3.8B | $2.9B | ||
| Q4 24 | $4.1B | $2.8B | ||
| Q3 24 | $3.4B | $2.8B | ||
| Q2 24 | $3.3B | $2.9B | ||
| Q1 24 | $3.3B | $2.8B |
负债/权益比ANDERGEN
| Q4 25 | 0.45× | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-77.1M | $17.6M |
| 自由现金流率自由现金流/营收 | -23.4% | 8.9% |
| 资本支出强度资本支出/营收 | 21.5% | 4.1% |
| 现金转化率经营现金流/净利润 | -0.09× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $-56.1M | $93.9M |
8季度趋势，按日历期对齐
经营现金流ANDERGEN
| Q4 25 | $-6.2M | $25.7M | ||
| Q3 25 | $233.9M | $48.1M | ||
| Q2 25 | $299.3M | $28.6M | ||
| Q1 25 | $-350.0M | $15.0M | ||
| Q4 24 | $268.8M | $39.2M | ||
| Q3 24 | $-2.1M | $49.3M | ||
| Q2 24 | $304.4M | $42.2M | ||
| Q1 24 | $-239.6M | $44.7M |
自由现金流ANDERGEN
| Q4 25 | $-77.1M | $17.6M | ||
| Q3 25 | $167.0M | $43.4M | ||
| Q2 25 | $250.5M | $21.5M | ||
| Q1 25 | $-396.6M | $11.4M | ||
| Q4 24 | $212.9M | $33.6M | ||
| Q3 24 | $-40.0M | $42.3M | ||
| Q2 24 | $275.8M | $37.4M | ||
| Q1 24 | $-266.4M | $36.4M |
自由现金流率ANDERGEN
| Q4 25 | -23.4% | 8.9% | ||
| Q3 25 | 56.5% | 23.0% | ||
| Q2 25 | 46.8% | 11.8% | ||
| Q1 25 | -106.9% | 6.8% | ||
| Q4 24 | 63.1% | 19.3% | ||
| Q3 24 | -17.2% | 27.3% | ||
| Q2 24 | 56.0% | 24.3% | ||
| Q1 24 | -78.0% | 24.0% |
资本支出强度ANDERGEN
| Q4 25 | 21.5% | 4.1% | ||
| Q3 25 | 22.6% | 2.5% | ||
| Q2 25 | 9.1% | 3.9% | ||
| Q1 25 | 12.6% | 2.1% | ||
| Q4 24 | 16.6% | 3.2% | ||
| Q3 24 | 16.3% | 4.5% | ||
| Q2 24 | 5.8% | 3.1% | ||
| Q1 24 | 7.8% | 5.5% |
现金转化率ANDERGEN
| Q4 25 | -0.09× | 1.93× | ||
| Q3 25 | 11.61× | 3.23× | ||
| Q2 25 | 38.10× | 1.92× | ||
| Q1 25 | -1232.46× | 2.57× | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | 12.70× | ||
| Q1 24 | -42.94× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
RGEN
暂无分部数据
